Recently, it was also shown that the resistance of prostate cancer cells to the next-generation antiandrogen, enzalutamide, is due to increased expression of p52, which is mediated by aberrant AR activation and AR splice variant production [18]. Here, NFKB2 is linked to prostate carcinoma.